recurrent singleton preterm birth

recurrent singleton preterm birth postThis study investigated patient preferences for administration-related attributes of treatments used to reduce the risk of recurrent preterm birth and drivers of treatment adherence propensity and was funded by AMAG Pharmaceuticals, Inc. All materials have undergone peer review according to Women’s Healthcare standards.

Download here to view the full study.


Please enter your comment!
Please enter your name here


This site uses Akismet to reduce spam. Learn how your comment data is processed.